A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
To enhance engagement with the company's shareholder base,
Shareholders can submit questions by visiting: https://app.saytechnologies.com/fractyl-health-2026-q3. This Q&A platform will remain open until
About Fractyl Health
Fractyl is a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. The Company’s lead product candidate, Revita, is an endoscopic procedural therapy in pivotal development for post-GLP-1 weight maintenance. Fractyl’s goal is to change the course of metabolic disease, advancing treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.
Contact?
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
Source: Fractyl Health, Inc.
